Intratumoral immune triads in elimination of solid tumors
Patrick Hwu shared on X:
“CD8+ ‘killer’ T cells can eliminate tumor cells. However, they can become dysfunctional in the tumor microenvironment. In a recent study, Andrea Scheitinger’s lab demonstrated that CD4+ T cells can reprogram dysfunctional CD8+ T cells to eliminate tumor cells if they interact with the same dendritic cell in the tumor microenvironment. Discovering ways to increase these CD4/CD8/DC triads in tumors may lead to better responses in patients.
Here’s a link to the full article.”
Source: Dr. Patrick Hwu/X
Dr. Patrick Hwu, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed
seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.
Before joining, Dr. Hwu held numerous leadership roles at The University of Texas
Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023